![]() ![]() "We wish we didn't have to do this, but the system is set up in a way that without this bold move, patients wouldn't get access and be able to afford Auvi-Q," Kaleo Chief Executive Spencer Williamson said in a telephone interview with CNBC Thursday. It's an example of the complicated economics that govern drug pricing. patients with commercial insurance will have no out-of-pocket costs for the devices, plus free product for those who don't have insurance and have a household income of less than $100,000. Plus it will offer a program it calls Auvi-Q AffordAbility that guarantees U.S. It guarantees a cash price of $360 for two auto-injectors. The price? A whopping $4,500 for two auto-injectors.īut not so fast, Kaleo said. The talking auto-injector competitor to Mylan's billion-dollar allergy attack remedy, the Auvi-Q, will return to market Feb. ![]() ![]() Competition for the EpiPen keeps mounting. ![]()
0 Comments
Leave a Reply. |